Literature DB >> 30120042

Can radiomics personalise immunotherapy?

Issam El Naqa1, Randall K Ten Haken2.   

Abstract

Mesh：

Substances：

Year:  2018        PMID： 30120042     DOI： 10.1016/S1470-2045(18)30429-7

Source DB:  PubMed          Journal:  Lancet Oncol        ISSN： 1470-2045            Impact factor:   41.316


× No keyword cloud information.
  7 in total

1.  The Promise of Digital Biopsy for the Prediction of Tumor Molecular Features and Clinical Outcomes Associated With Immunotherapy.

Authors:  Giuseppe Luigi Banna; Timothée Olivier; Francesco Rundo; Umberto Malapelle; Filippo Fraggetta; Massimo Libra; Alfredo Addeo
Journal:  Front Med (Lausanne)       Date:  2019-07-31

Review 2.  Application of Radiomics for Personalized Treatment of Cancer Patients.

Authors:  Yiming Meng; Jing Sun; Na Qu; Guirong Zhang; Tao Yu; Haozhe Piao
Journal:  Cancer Manag Res       Date:  2019-12-30       Impact factor: 3.989

3.  Incorporating radiomics into clinical trials: expert consensus endorsed by the European Society of Radiology on considerations for data-driven compared to biologically driven quantitative biomarkers.

Authors:  Laure Fournier; Lena Costaridou; Luc Bidaut; Nicolas Michoux; Frederic E Lecouvet; Lioe-Fee de Geus-Oei; Ronald Boellaard; Daniela E Oprea-Lager; Nancy A Obuchowski; Anna Caroli; Wolfgang G Kunz; Edwin H Oei; James P B O'Connor; Marius E Mayerhoefer; Manuela Franca; Angel Alberich-Bayarri; Christophe M Deroose; Christian Loewe; Rashindra Manniesing; Caroline Caramella; Egesta Lopci; Nathalie Lassau; Anders Persson; Rik Achten; Karen Rosendahl; Olivier Clement; Elmar Kotter; Xavier Golay; Marion Smits; Marc Dewey; Daniel C Sullivan; Aad van der Lugt; Nandita M deSouza
Journal:  Eur Radiol       Date:  2021-01-25       Impact factor: 5.315

4.  A Machine learning model trained on dual-energy CT radiomics significantly improves immunotherapy response prediction for patients with stage IV melanoma.

Authors:  Andreas Stefan Brendlin; Felix Peisen; Haidara Almansour; Saif Afat; Thomas Eigentler; Teresa Amaral; Sebastian Faby; Adria Font Calvarons; Konstantin Nikolaou; Ahmed E Othman
Journal:  J Immunother Cancer       Date:  2021-11       Impact factor: 13.751

5.  Identification of Stage IIIC/IV EGFR-Mutated Non-Small Cell Lung Cancer Populations Sensitive to Targeted Therapy Based on a PET/CT Radiomics Risk Model.

Authors:  Dan Shao; Dongyang Du; Haiping Liu; Jieqin Lv; You Cheng; Hao Zhang; Wenbing Lv; Shuxia Wang; Lijun Lu
Journal:  Front Oncol       Date:  2021-11-02       Impact factor: 6.244

6.  Mitigation of noise-induced bias of PET radiomic features.

Authors:  Ananthi Somasundaram; David Vállez García; Elisabeth Pfaehler; Joyce van Sluis; Rudi A J O Dierckx; Elisabeth G E de Vries; Ronald Boellaard
Journal:  PLoS One       Date:  2022-08-25       Impact factor: 3.752

7.  Prediction of Early Response to Immune Checkpoint Inhibition Using FDG-PET/CT in Melanoma Patients.

Authors:  Ken Kudura; Florentia Dimitriou; Lucas Basler; Robert Förster; Daniela Mihic-Probst; Tim Kutzker; Reinhard Dummer; Joanna Mangana; Irene A Burger; Michael C Kreissl
Journal:  Cancers (Basel)       Date:  2021-07-29       Impact factor: 6.575
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.